Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 530233 | NSE Symbol : | ISIN : INE292C01011 | Industry : Pharmaceuticals - Indian - Bulk Drugs |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
15-May-2025	30-May-2025	Accounts	Auro Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 inter alia to consider and approve financial results for the quarter and year ended March 31 2025 and any other matter with the permission of chair. The Board Meeting to be held on 23/05/2025 has been revised to 30/05/2025 The Board Meeting to be held on 23/05/2025 has been revised to 30/05/2025 due to certain exigencies. (As per BSE Announcement Dated on 21/05/2025) Auro Laboratories Limited has submitted the Outcome of the Board Meeting held on May 30, 2025. (As Per BSE Announcement Dated on: 30/05/2025)
07-Feb-2025	14-Feb-2025	Quarterly Results	AURO LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve 1. Unaudited Financial Results of the Company for quarter ended December 31 2024 along with Limited Review Report thereon. 2. Any other matter with the permission of the Chair. Attached herewith Unaudited Financial Results of the company for the Quarter ended December 31, 2024. (As Per BSE Announcement Dated on: 14/02/2025)
05-Nov-2024	11-Nov-2024	Quarterly Results	AURO LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2024 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter and half year ended September 30 2024 along with Limited Review Report and any other matter with the permission of the Chair.
31-Jul-2024	09-Aug-2024	Quarterly Results	AURO LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve 1. Unaudited Financial Results of the Company for quarter ended June 30 2024 along with Limited Review Report thereon. 2. Any other matter with the permission of the Chair. Pursuant to Regulation 30 & 33 of the SEBI(LODR), Regulations, 2015, we wish to inform you that the Board of Directors of the Company in their Meeting held today (i.e. Friday, August 09, 2024) inter alia, considered and approved Unaudited Financials Results for the quarter ended June 30, 2024 along with Limited Review Report received from the Statutory Auditor of the Company. (As per BSE Announcement Dated on 09/08/2024)
17-May-2024	25-May-2024	Accounts	AURO LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2024 inter alia to consider and approve the audited financial results for the quarter and year ended March 31 2024. Attached audited financial results along with statement of assets and liabilities, cash flow statement and report of auditors'' thereon for the quarter and year ended March 31, 2024 (As Per BSE Announcement dated on 25.05.2024) We are submitting herewith revised financial statements for the quarter and financial year ended March 31, 2024. We submit that due to some inadvertent error, other equity figures was not represented in the profit and loss statement, however, the same was shown under statement of assets and liabilities. Read less.. Revised outcome for revision in audited financial results for the quarter and year ended March 31, 2024 in respect of error as mentioned in letter attached. (As Per BSE Announcement Dated on 29.05.2024)
30-Mar-2024	30-Mar-2024	Change in Directors	We wish to inform you that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors, in their meeting held today i.e Saturday March 30, 2024, appointed Mr. Mahendra Kumar Daga (DIN: 10570354) as an Additional (Non-Executive & Independent) Director of the Company w.e.f April 1, 2024, subject to the approval of the shareholders of the Company.
31-Jan-2024	06-Feb-2024	Quarterly Results	AURO LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2024 inter alia to consider and approve unaudited financial results for quarter ended December 31 2023 As attached Outcome of meeting dated Feb 6, 2024 (As per BSE Announcement Dated on 06/02/2024)
22-Dec-2023	22-Dec-2023	Change in Other Executives	We wish to inform you that the Board of Directors had in their meeting held today on December 22, 2023, approved appointment of Ms. Shaan Jain and Chief Financial Officer and Key Managerial Personnel of the Company with effect from December 22, 2023.
03-Nov-2023	09-Nov-2023	Quarterly Results	AURO LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve unaudited financial results for the quarter and half year ended September 30 2023 and other matters We wish to inform that the Board of directors of our Company in their meeting held today, i.e November 9, 2023 has considered and approved the unaudited financial results for the quarter and half year ended September 30, 2023. Results (As Per BSE Announcement Dated on 09/11/2023)
23-Aug-2023	23-Aug-2023	Change in Directors	We wish to inform you that the Board of Directors have in their meeting today August 23, 2023 approved appointment of Mr. Vishal Kailashchandra Jhunjhunwala (DIN: 00359872) as an additional Director(Non-Executive & Independent) on the Board of the Company, subject to that approval of shareholders in the ensuing AGM.
21-Jul-2023	31-Jul-2023	Quarterly Results	AURO LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2023 inter alia to consider and approve the unaudited financial results for the quarter ended June 30 2023 along with the limited review report thereon. AURO LABORATORIES LIMITED has informed BSE about Board Meeting to be held on 31 Jul 2023 to consider financial statements for the period ended June 2023. Financial results. Outcome of Board meeting dated July 31, 2013 for approval of unaudited financial results for the quarter ended June 30, 2023 Please find enclosed unaudited financial results for the quarter ended June 30, 2023. Please find enclosed intimation of change in auditors as per Reg 30 of SEBI (LODR) Regulations, 2015 (As per BSE Announcement Dated on 31/07/2023)
08-May-2023	16-May-2023	Accounts	AURO LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2023 inter alia to consider and approve AURO LABORATORIES LTD has informed BSE that the Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday May 16 2023 inter alia to consider and approve Audited Financial Results of the Company for quarter and year ended March 31 2023 along with reports thereon and any other matter with the permission of the Chair. In accordance with the Companys Code of Conduct to Regulate Monitor and Report trading by Designated Persons and Immediate Relatives of Designated Persons pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 the trading window for dealing in the securities of the Company has been closed from April 01 2023 and shall reopen 48 hours after the declaration of Financial Results to the Stock Exchange. Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting held today (i.e. Tuesday, May 16, 2023), has transacted the following business: 1. Approved the Audited Financial Results of the Company for the quarter and year ended March 31, 2023 as recommended by the Audit Committee. In this regard, we are enclosing herewith: Audited Financial Results for the quarter and year ended March 31, 2023 along with the Statement of Assets and Liabilities of the Company and Cash Flow Statement as on that date. Auditors Report on the Financial Results for the quarter & year ended March 31, 2023. Declaration regarding Auditor Report with unmodified opinion on the Audited Standalone Financial Results of the Company for the Financial Year ended on March 31, 2023. (As Per BSE Announcement Dated on 16.05.2023)
31-Jan-2023	13-Feb-2023	Quarterly Results	AURO LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2023 inter alia to consider and approve the unaudited Financial Results for the quarter ended December 31 2022 along with limited review report thereon and any other matters with the permission of the Chair. In accordance with the Companys Code of Conduct to Regulate Monitor and Report trading by Designated Persons and Immediate Relatives of Designated Persons pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 the trading window for dealing in the securities of the Company has been closed from December 31 2022 and shall reopen 48 hours after the declaration of Financial Results to the Stock Exchange. Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting held today (i.e. Monday, February 13, 2023), has transacted the following business: Considered and approved the Unaudited Financial Results of the Company for the quarter ended on December 31, 2022 as recommended by the Audit Committee. (As Per BSE Announcement Dated on 13/02/2023)
04-Nov-2022	14-Nov-2022	Quarterly Results	AURO LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve 1. To consider and approve the unaudited Financial Results for the quarter and half year ended September 30 2022 along with limited review report thereon. 2. Any other matters with the permission of the Chair. Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting held today (i.e. Monday, November 14, 2022), has transacted the following business: 1. Considered and approved the Unaudited Financial Results of the Company for the quarter & half year ended on September 30, 2022 as recommended by the Audit Committee In this regard, we are enclosing herewith: Unaudited Financial Results for the quarter & half year ended September 30, 2022. Statement of Assets and Liabilities as on September 30, 2022. Cash Flow Statement for the quarter and half year ended September 30, 2022. Limited Review Report received from the Statutory Auditor of the Company. The Meeting of the Board of Directors commenced at 2.30 p.m. and concluded at 3.15 p.m. Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting held today (i.e. Monday, November 14, 2022), has transacted the following business: 1. Considered and approved the Unaudited Financial Results of the Company for the quarter & half year ended on September 30, 2022 as recommended by the Audit Committee. In this regard, we are enclosing herewith: Unaudited Financial Results for the quarter & half year ended September 30, 2022. Statement of Assets and Liabilities as on September 30, 2022. Cash Flow Statement for the quarter and half year ended September 30, 2022. Limited Review Report received from the Statutory Auditor of the Company. The Meeting of the Board of Directors commenced at 2.30 p.m. and concluded at 3.15 p.m. (As Per BSE Announcement Dated on 14.11.2022)
19-Jul-2022	02-Aug-2022	Quarterly Results	AURO LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2022 inter alia to consider and approve the unaudited quarterly financial results for the quarter ended June 30 2022 along with limited review report thereon. Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting held today (i.e. Tuesday, August 02, 2022) transacted the following business: 1. Considered and approved the Unaudited Financial Results of the Company for the quarter ended on June 30, 2022 as recommended by the Audit Committee. In this regard, we are enclosing herewith: Unaudited Financial Results for the quarter ended on June 30, 2022 Limited Review Report received from the Statutory Auditors of the Company (As Per BSE Announcement Dated on 02.08.2022)

1 2

LOGIN HERE

Auro Laboratories Ltd

Board Meeting